Congress Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Congress Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$11.7M	Sell	269,931 -2,575	-0.9%	-$93.7K	0.11%	216
2025 Q1	$9.42M	Buy	+272,506	New	+$9.19M	0.11%	215

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Congress Wealth Management's BBIO Position: Q2 2025 in Review

Congress Wealth Management reduced its BridgeBio Pharma (BBIO) stake by 0.94% in Q2 2025, selling an estimated $93.7K and leaving 269,931 shares worth $11.7M. The position accounts for 0.11% of the portfolio, ranked #216.

Congress Wealth Management first reported a position in BBIO in Q1 2025 and has held it in 2 quarters since. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Congress Wealth Management held 269,931 shares of BridgeBio Pharma worth $11.7M as of Q2 2025.
Congress Wealth Management sold 2,575 BridgeBio Pharma shares in Q2 2025, an estimated $93.7K.
BridgeBio Pharma made up 0.11% of Congress Wealth Management's portfolio in Q2 2025, its #216 holding.
Congress Wealth Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 2 quarters since.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Congress Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.